Acute myeloid leukemia in adults: Experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán from 2003 to 2008;Experiencia del INCMNSZ en pacientes adultos con leucemia mieloide aguda. Cohorte 2003-2008

Revista de Investigacion Clinica

Volumn 62, Issue 2, 2010, Pages 100-108

  Buitrón Santiago, Natalie ^a   Arteaga Ortiz, Luis ^a   Rosas López, Adriana ^a   Aguayo, Álvaro ^a   López Karpovitch, Xavier ^a   Crespo Solís, Erick ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

3+7 protocol; Acute myeloid leukemia; Autologous bone marrow transplant; High doses of cytarabine

Indexed keywords

CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADULT DISEASE; AGED; APLASIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTOSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEXICO; MORTALITY; REMISSION; RISK FACTOR; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 77954193231     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Stone R. Acute myeloid leukemia. Hematology 2004: 98-117.
2. Tallman M, Gilliland G, Rowe J. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-63. (Pubitemid 41130866)
3. Jaffe E, Stein H, Vardiman JW. (2001) WHO: Classification of Tumours. Tumours of Haematopoietic and Lymhoid Tissue. IARC Press, Lyon.
4. Yates JW, Wallace HR, Ellison RR, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973; 57: 485.
5. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorrubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666-74.
6. Vogler W, Velez-Garcia E, Weiner R, et al. Phase HI trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992; 10: 1103-11.
7. Buchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93(12): 4116-24.
8. Lobato-Mendizabal E, Ruiz-Arguelles G, Gomez-Almaguer D, et al. Tratamiento a largo plazo y factores pronósticos en leucemia aguda mieloblástica del adulto. Experiencia del grupo INNSZ (Puebla-Monterrey-México). Rev Invest Clin 1991; 43: 215-22.
9. Bennett J. Proposals for the classification of the acute leukemias. Br J Haematol 1976; 33: 451-8.
10. Omura G, Vogler R, Lefante J, et al. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy of BCG immunotherapy. Cancer 1982; 49: 1530-6.
11. Mayer R, Davis R, Schiffer C, et al. intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896-903. (Pubitemid 24299870)
12. Byrd J, Mrozek K, Dodge R, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-36.
13. Ugarte A, Villasis A, Hernández ME, Crespo E, Ruiz GM, Ponce-De-León, et al. Utilidad de la profilaxis con fluoroquinolonas durante la neutropenia grave inducida por quimioterapia en pacientes con leucemia aguda, en un hospital de referencia de la ciudad de México con alla prevalencia de resistencia a fluoroquinolonas. Rev Invest Clin 2006; 58: 547-54.
14. Cheson BD, Cassilth PA, Head DR, Schiffer, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-19.
15. Miller K. Clinical manifestations of acute leukemia. In: Hoffman Hematology, Basic Principles and Practice. 5th. Ed. Churchill and Livingstone; 2008.
16. Pillay Y, McLellan G, Davison G, et al. CD7 expression does not predict for poor outcome in acute myeloblastic leukemia. Blood 1995; 85: 3357-9.
17. Griffin J, Davis R, Nelson D, et al. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood 1986; 68: 1232-41. (Pubitemid 17228797)
18. Byrd J, Mrozek K, Dodge R. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-36.
19. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood 1998; 92: 2322-33.
20. Slovak M, Kopecky K, Cassileth P, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/ Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075-83.
21. Jeha S, Giles F. Chapter 10: Acute myeloid leukemia in American Society of Hematology Self Assesment Program. 2007.
22. Infante-Sierra H, Crespo-Solis E, Lopez-Karpovitch X, et al. Reporte preliminar: evaluación del esquema 7+3 en leucemia mieloide aguda y tasa de mortalidad temprana en una cohorte retrospective versus cohorte prospectiva. Rev Fac Med UNAM 2008; 51(4): 150-5.
23. Estey E, Smith TL, Keating MJ, et al. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 1989; 3(4): 257-63. (Pubitemid 19092757)
24. Moore J, Dodge R, Amrein P, et al. Granulocyte-Colony Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood 1997; 89: 780-8.
25. Khalidi HS, Medeiros LJ, Chang KL, et al. The immunopheno-type of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol 1999; 109(2): 211-20.
26. Jiao B, Wu CF, Liang Y, et al. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 2009, 21 de mayo (publicación electrónica antes de la impresa).
27. Zittoun R, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217-23.
28. Harousseau JL, Cahn J, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997; 90: 2978-86.
29. Cassileth P, Harrington D, Apperlbaum F, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-56.
30. Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation Study. Blood 1997; 90: 2931-8. (Pubitemid 27444187)
31. Löwenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology 2008: 1-11.